Dynavax Technologies Corp Sustainability Reports

Dynavax Technologies Corp. is a commercial-stage biopharmaceutical company that develops and commercializes innovative vaccines. Its key commercial products include the HEPLISAV-B vaccine for adult hepatitis B and the CpG 1018 vaccine adjuvant.

Sector: Manufacturing

Country: United States

Exchange: Nasdaq

LEI: 549300T5URIXWDILX594

FIGI: BBG001S7HTB7

7 reports from 2007 to 2022

• Dynavax Technologies Corp 2022 Annual Report
• Dynavax Technologies Corp 2017 Form 10-K
• Dynavax Technologies Corp 2016 Form 10-K (Annual Report)
• Dynavax Technologies Corp 2014 Annual Report
• Dynavax Technologies Corp 2013 Form 10-K